Sample records for PIP (tid)
from WorldWideScience.org

Sample records 1 - 15 shown.



1

Polimorfismo +49 A/G del gen del antígeno 4 del linfocito T citotóxico (CTLA-4) en la diabetes tipo 1: Asociación con el perfil de anticuerpos y citoquinas/ +49 A/G genetic polymorphism of cytotoxic T lymphocyte associated antigen 4 (CTLA-4) in type 7 diabetes: Association with autoantibodies and cytokines

Pérez B, Francisco; Codner D, Ethel; Ángel B, Bárbara; Balic N, Iván; Carrasco P, Elena
2009-03-01

Resumen en inglés Background: Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) has been one ofthe non HLA genes more commonly studied in type 1 diabetes mellitus (TID). CTLA-4 is a co-stimulation protein that has a key role in the negative regulation ofT cells and is related with a functional cytokine imbalance, generating a T helper (Th) 1 over Th2 dominance. Aim: To analyze the association of +49 A/G polymorphism of CTLA-4 and its relationship with autoantibodies and cytokine express (mas) ion in recently diagnosed TID patients. Patients and Methods: CTLA-4 genetic variants and auto-antibody levéis were studied in 260 chiídren with TID and 255 healthy chiídren matched by age and gender +49 A/G polymorphism of CTLA-4 was studied by polymerase chain reaction and restriction fragmentpolymorphism (PCR-RFLP). Autoantibody levéis were measured by conventional ELISA. A panel of60 cytokines was studied simultaneously by serum array analysis in 15 TID and 15 healthy controls stratified according CTLA-4 genotype. Results: The +49 A/G genetic frequency was similar in TID cases and healthy chiídren. A positive anti-GAD65 and anti-IA-2 level was observed in 673% of TID group. This percentage was increased among GG carriers (79.4% to GAD65 and 70.6% to IA-2). Finally, TID patients carrying this genotype showed a high expression of interleukin 2, 10, tumor necrosis factor alpha and interferon gamma. Conclusions: The +49 A/G polymorphism of CTLA-4 was similar in diabetic and control chiídren. Among patients with TID and carriers of GG genotype, a higher frequency of anti-GAD65 and a preferential Thl cytokine expression profile was observed

Scientific Electronic Library Online (Spanish)

2

Tratamiento de la neumonía del adulto adquirida en la comunidad/ Treatment of community-acquired pneumonia in adults

Díaz F, Alejandro; Labarca L, Jaime; Pérez C, Carlos; Ruiz C, Mauricio; Wolff R, Marcelo
2005-01-01

Resumen en inglés Appropriate antibiotic treatment reduces the duration of symptoms associated to pneumonia, the risk of complications and mortality. In most cases, it is not possible to identify the etiologic agent so antibiotic treatment is empirically prescribed. In Chile, one third of Streptococcus pneumoniae strain isolates has diminished susceptibility to penicillin; in-vitro erythromycin resistance is about 10-15% and cefotaxime resistance 2-10%. It is recommended to classify patien (mas) ts with community acquired pneumonia in four risk categories: Group 1: patients under 65 years without co-morbidities, in ambulatory attendance. Treatment: oral amoxicillin 1 g TID, 7 days. Group 2: patients over 65 years and / or co-morbidities, in ambulatory attendance. Treatment: oral amoxicillin/clavulanate 500/125 mg TID or 875/125 mg BID, or cefuroxime 500 mg BID, 7 days. Group 3: patients admitted to general wards with criteria of moderate severity. Treatment: ceftriaxone 1-2 g once a day or cefotaxime 1 g TID, IV, 7-10 days. Group 4: patients with severe CAP that must be interned into ICU. Treatment: ceftriaxone 2 g once a day or cefotaxime 1 g TID, IV, associated to erythromycin 500 QID, levofloxacin 500-1.000 mg once a day, or moxifloxacin 400 mg/once a day, IV, 10-14 days. In the presence of allergy to or treatment failure with betalactam drugs and/or positive serology for Mycoplasma, Chlamydia or Legionella sp it is recommended to add: erythromycin 500 mg QID, IV or oral, oral clarithromycin 500 mg BID, or oral azythromycin 500 mg once a day

Scientific Electronic Library Online (Spanish)

3

Uso de flavonoides (hesperidina) en el tratamiento de venas varicosas vesicales sangrantes/ Treatment of bladder varicose veins with flavonoids (hesperidina)

Granados Loarca, E.A.
2003-10-01

Resumen en español OBJETIVO: Informar del uso de los Flavonoides (Hesperidina) en el tratamiento de varices vesicales, y su eficacia. PACIENTES: Se informa de 4 casos que acudieron por hematuria, y que en la cistoscopia se observó varices vesicales, sangrantes en 2 casos; en ellos se utilizó Hesperidina 150 Mg. bid o tid por 30 días. RESULTADOS: Fueron buenos, en los 2 casos que sangraban desapareció la hematuria y en los 4 casos en la cistoscopia de control las varices habían desapare (mas) cido. CONCLUSIONES: El tratamiento antivaricoso o anti-hemorroidal puede ser útil en el tratamiento de varices vesicales. Se debe de dar como mínimo por 30 días Resumen en inglés OBJECTIVE: To inform of the use of the Flavonoids in the treatment of bladder varicose veins, and their effectiveness. PATIENT: It is informed of 4 cases that went for haematuria, and that in the cistoscopy one observes bladder varicose veins, bleeding in 2 cases, in them you uses Hesperidina 150 mg bid or tid for 30 days. RESULTS: They were good, the 2 cases that bled the haematuria disappeared and in the 4 cases in the control cistoscopy the varicose veins had disappear (mas) ed. CONCLUSIONS: The treatment antivaricose or antihemorrhoidal can be useful in the treatment of bladder varicose veins. It should be given as minimum by 30 days.

Scientific Electronic Library Online (Spanish)

4

Tratamiento de la neumonía del adulto adquirida en la comunidad/ TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

Díaz F, Alejandro; Labarca L, Jaime; Pérez C, Carlos; Ruiz C, Mauricio; Wolff R, Marcelo
2005-04-01

Resumen en español El tratamiento antimicrobiano apropiado reduce la duración de la sintomatología asociada a la neumonía, el riesgo de complicaciones y la mortalidad. En la mayoría de los casos, no es posible identificar el agente microbiológico que ocasiona la infección y por esto el tratamiento antibacteriano se prescribe en forma empírica. En Chile, un tercio de las cepas de Streptococcus pneumoniae muestra susceptibilidad disminuida a penicilina; mientras que la resistencia a er (mas) itromicina fluctúa entre 10-15% y a cefotaxima entre 2-10%. Se recomienda clasificar a los pacientes con neumonía comunitaria en cuatro categorías de riesgo: Grupo 1: pacientes bajo 65 años de edad, sin comorbilidad de manejo ambulatorio. Tratamiento: amoxicilina 1 gramo cada 8 horas vía oral durante 7 días. Grupo 2: pacientes sobre 65 años de edad y/o con comorbilidad de manejo ambulatorio. Tratamiento: amoxicilina/ácido clavulánico 500/125 mg cada 8 horas ó 875/125 mg cada 12 horas, o cefuroxima 500 mg cada 12 horas vía oral durante 7 días. Grupo 3: pacientes hospitalizados en sala de cuidados generales que tienen criterios de gravedad moderada. Tratamiento: ceftriaxona 1-2 g/día o cefotaxima 1 g cada 8 horas EV durante 7-10 días. Grupo 4: pacientes con neumonía comunitaria grave que deben ser manejados en la UCI. Tratamiento: ceftriaxona 2 g/día o cefotaxima 1 g cada 8 horas EV asociado a eritromicina 500 mg cada 6 h, levofloxacina 500-1.000 mg/día, o moxifloxacina 400 mg/día EV durante 10-14 días. En presencia de alergia o fracaso de tratamiento con agentes b-lactámicos y/o serología positiva para Mycoplasma, Chlamydia o Legionella sp se recomienda agregar: eritromicina 500 mg cada 6 h EV o VO, claritromicina 500 mg cada 12 h VO, o azitromicina 500 mg/día VO Resumen en inglés Appropriate antibiotic treatment reduces the duration of symptoms associated to pneumonia, the risk of complications and mortality. In most cases, it is not possible to identify the etiologic agent so antibiotic treatment is empirically prescribed. In Chile, one third of Streptococcus pneumoniae strain isolates has diminished susceptibility to penicillin; in-vitro erythromycin resistance is about 10-15% and cefotaxime resistance 2-10%. It is recommended to classify patien (mas) ts with community acquired pneumonia in four risk categories: Group 1: patients under 65 years without co-morbidities, in ambulatory attendance. Treatment: oral amoxicillin 1 g TID, 7 days. Group 2: patients over 65 years and / or co-morbidities, in ambulatory attendance. Treatment: oral amoxicillin/clavulanate 500/125 mg TID or 875/125 mg BID, or cefuroxime 500 mg BID, 7 days. Group 3: patients admitted to general wards with criteria of moderate severity. Treatment: ceftriaxone 1-2 g once a day or cefotaxime 1 g TID, IV, 7-10 days. Group 4: patients with severe CAP that must be interned into ICU. Treatment: ceftriaxone 2 g once a day or cefotaxime 1 g TID, IV, associated to erythromycin 500 QID, levofloxacin 500-1.000 mg once a day, or moxifloxacin 400 mg/once a day, IV, 10-14 days. In the presence of allergy to or treatment failure with betalactam drugs and/or positive serology for Mycoplasma, Chlamydia or Legionella sp it is recommended to add: erythromycin 500 mg QID, IV or oral, oral clarithromycin 500 mg BID, or oral azythromycin 500 mg once a day

Scientific Electronic Library Online (Spanish)

5

Citrato de Ranitidina Bismuto con Claritromicina y Amoxacilina vs Terapia Triple con inhibidores de la bomba de Protones: Omeprazol o Lansoprazol en el tratamiento de la infección por Helicobacter Pylori

González, JC; Louis, C; Salazar, P
2001-02-01

Resumen en español El objetivo de nuestro trabajo es investigar la eficacia de 2 semanas de tratamiento triple con Amoxacilina, Claritromicina, y Citrato de Ranitidina Bismuto (CRB) u Omeprazol o Lansoprazol en la erradicación de la infección por Helicobacter pylori (Hp) en pacientes con enfermedad úlcero-péptica. Se incluyeron 152 pacientes consecutivos con enfermedad úlcero-péptica, cuya infección por Hp fue confirmada por histología, fueron distribuidos al azar para recibir CRB 4 (mas) 00 mg bid (grupo A) u Omeprazol 20 mg bid (grupo B) o Lansoprazol 30 mg bid (grupo C) en combinación con Claritromicina 500 mg bid y Amoxacilina 500 mg tid por 2 semanas. El Hp fue erradicado en el 50%, 73% y 84% de los pacientes del grupo A, B y C respectivamente. La diferencia fue estadísticamente significativa para una menor erradicación en el grupo A (p Resumen en inglés The purpose of this study is to investigate the efficacy of 2-week triple therapy with amoxycillin, clarithromycin, and ranitidine bismuth citrate (RBC) or omeprazole or lanzoprazole in curing Helicobacter pylori (Hp) infection in patients with peptic ulcer disease. The study included 152 consecutive patients with peptic disease, in whom Hp infection was confirmed by histology, were randomly assigned to a 2-week treatment with either 400 mg bid RBC (A group) or 20 mg bid (mas) Omeprazole (B group), or 30 mg bid Lanzoprazole (C group) in combination with 500 mg bid clarithromycin and 500 mg tid amoxycillin. Eradication of Hp was successful in 50% of the patients in the A group, and 73% of the patients in the B group, and 84% of the patients in the C group. The difference was significant for a low percentage of eradication in A group (p

Scientific Electronic Library Online (Spanish)

6

Terapia triple de corto tiempo con azitromicina, amoxicilina y omeprazo para la erradicación del Helicobacter pylori/ Short-term therapy with azithromycin, amoxycilin and omeprazole for the eradication of Helicobacter pylori

Flores O, Sergio; Opazo S, Hector; Valderrama T, Danilo; Aguilera B, Renato; Marchese P, Annabella; Valderrama T, Sergio
2000-05-01

Resumen en inglés Background: the high cost and complexity of therapeutic schemes for the eradication of Helicobacter pylori has stimulated the search of simpler and cheaper treatment options. Aim: To evaluate the efficacy of 3 days of azithromycin 500 mg od, 7 days of amoxycilin 750 mg tid and omeprazole, 20 (Group A) or 40 mg (Group B) on randomization, as a treatment for Helicobacter pylori infection in patients with endoscopically diagnosed peptic ulcer. Methods: H. pylori status of pe (mas) ptic ulcer patients was pathologically confirmed by the examination of five gastric biopsies using the Giemsa stain and by rapid urease testing in two gastric biopsies. H. pylori status was reassessed not less than 28 days after completing treatment. Adverse events and compliance were evaluated. Results: Fifty four patients (29 men, 25 women, mean age 48 years) were enrolled, 28 in Group A and 27 in Group B. Per protocol the infection was cured in 58,8% of patients (30/51; 95% CI: 45-73%). On an intention to treat basis, H pylori infection was cured in 55%. Minor side effects including diarrhea and nausea were reported by 32% of patients. Ninety five per cent of patients consumed more than 95% of prescribed medications. H. pylori was successfully erradicated in 61% of group A and 57% of group B patients (p= NS). Conclusion: Short term therapy with azithromycin was poorly effective in curing H. pylori infection. The compliance was excellent. Increasing Omeprazole from 20 to 40 mg/day did not improve treatment effectiveness. (Rev Méd Chile 2000; 128: 509-12)

Scientific Electronic Library Online (Spanish)

7

Efecto de la pentoxifilina en la supervivencia, la función cardiaca y en la hemodinámica portal y sistémica de la cirrosis alcohólica avanzada: a randomized double-blind placebo-controlled trial/ Effect of pentoxiphylline on survival, cardiac function, and portal and systemic hemodynamics in advanced alcoholic cirrhosis

Fernández-Rodríguez, C. M.; Lledó, J. L.; López-Serrano, P.; Gutiérrez, M. L.; Alonso, S.; Pérez-Fernández, M. T.; Fernández Gil, M.; Pazos, R.; Tolon, R.; Hernández, T.; Sanz, P.
2008-08-01

Resumen en español Objetivo: valorar el efecto de la pentoxifilina (un potente inhibidor del factor de necrosis tumoral alfa) en la supervivencia, en la hemodinámica sistémica y portal y en la función cardiaca en la cirrosis alcohólica avanzada. Diseño: estudio aleatorizado, doble-ciego, controlado con placebo. Contexto: estudio unicéntrico utilizando grupos de pacientes en paralelo para comparar pentoxifilina y placebo. Pacientes: se incluyeron 24 pacientes con cirrosis alcohólica ( (mas) 8 en estadio B de Child-Pugh y 16 en estadio C de Child-Pugh). Intervención: los pacientes fueron aleatorizados a recibir pentoxifilina (400 mg, 3 veces al día, n = 12) o placebo (n = 12) durante 4 semanas. Determinaciones: el objetivo principal fue la supervivencia a corto/largo plazo. Los objetivos secundarios fueron observar beneficios hemodinámicos (mejoría en la función cardiaca y/o en el índice de resistencias vasculares sistémicas o disminución de la presión portal). Resultados: la presión portal y la función cardiaca no se modificaron y no hubo diferencias en la supervivencia a corto y largo plazo entre los grupos tratados y placebo. Los índices de resistencia vascular sistémica y cardiaco cambiaron en el grupo de pentoxifilina (de 1.721 ± 567 a 2.082 ± 622 Din.seg ¹ cm-5 m-2 y de 4,17 ± 1,4 a 3,4 ± 0,9 lm-2, p = 0,05). Conclusiones: aunque la pentoxifilina parece producir algún beneficio hemodinámico a corto plazo en pacientes con cirrosis alcohólica avanzada, no tiene efecto sobre la tasa de supervivencia, la función cardiaca ni sobre la presión portal en estos pacientes. Resumen en inglés Objective: to assess the effect of pentoxiphylline (a potent inhibitor of tumor necrosis factor alpha) on survival, on systemic and portal hemodynamics, and on cardiac function in patients with alcoholic cirrhosis. Design: a randomized double-blind placebo-controlled trial. Setting: a single center using parallel groups of patients to compare pentoxiphylline with placebo. Patients: we recruited 24 patients with alcoholic cirrhosis (8 Child-Pugh B and 16 Child-Pugh C). Int (mas) erventions: patients were randomly assigned to receive pentoxiphylline (400 mg tid; n = 12) or placebo (n = 12) over a 4-week period. Outcome measures: the primary outcome was to extend short-term and long-term survival. Secondary outcomes included hemodynamic benefits (improvement in cardiac function and/or systemic vascular resistance index, or decrease in portal pressure). Results: portal pressure and cardiac function remained unchanged and there were no significant differences in short-term or long-term survival between treatment and placebo groups. The group on pentoxiphylline increased systemic vascular resistance and decreased cardiac indices (from 1,721 ± 567 to 2,082 ± 622 dyn.sec-1 cm-5 m-2 and from 4.17 ± 1.4 to 3.4 ± 0.9 l.m-2, p = 0.05). Conclusions: although pentoxiphylline seems to provide some short-term aemodynamic benefits in patients with advanced alcoholic cirrhosis, this drug has no effect on survival or portal pressure in these patients.

Scientific Electronic Library Online (Spanish)

9

La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática/ Cisapride does not modify prolonged Q-T interval in patients with liver cirrhosis

Quera P, Rodrigo; Madrid S, Ana María; Ugalde P, Héctor; Defilippi C, Carlos
2000-08-01

Resumen en inglés Background: Abnormal small bowel motility, observed in liver cirrhosis, can be reversed with cisapride. Since both cisapride and liver disease are associated with prolonged QT interval, the possibility of adverse cardiovascular effects might be expected with cisapride treatment in these patients. Aim: To evaluate QT interval and other electrocardiographic changes during long term treatment with cisapride in cirrhotic patients. Patients and methods: Forty seven cirrhotic p (mas) atients were studied. Electrocardiogram was recorded and the QT interval corrected according to Bazzett’s formula was determined (normal value

Scientific Electronic Library Online (Spanish)

10

Interpretación de la cápsula endoscópica: el papel del personal no especializado/ Capsule endoscopy interpretation: The role of physician extenders

Fernández-Urién, I.; Espinet, E.; Pérez, N.; Betés, M.; Herráiz, M.; Carretero, C.; Muñoz-Navas, M.
2008-04-01

Resumen en español Introducción y objetivos: la cápsula endoscópica (CE) ha supuesto una nueva era en el estudio del intestino delgado. No obstante, el tiempo empleado por el gastroenterólogo en este procedimiento es mayor del deseable y no se han evaluado completamente alternativas al personal especializado. El objetivo de este estudio es evaluar la precisión de personal no especializado en la interpretación de la CE. Material y métodos: un gastroenterólogo con experiencia en CE y (mas) personal no especializado revisaron independientemente 20 procedimientos. Los hallazgos de cada participante eran desconocidos por el resto. Un consenso formado por los participantes y un segundo gastroenterólogo fue empleado como gold standard. Se analizaron número, tipo y localización de las imágenes seleccionadas y tiempo de evacuación gástrica (tEG), tiempo de tránsito en intestino delgado (tTID) y tiempo empleado por los participantes. Resultados: la sensibilidad y la especificidad global fueron del 79 y 99% para el gastroenterólogo; del 86 y 43% para la enfermera; y del 80 y 57% para el residente. Las 34 lesiones "mayores" consideradas por consenso fueron detectadas por los tres participantes. El acuerdo entre consenso y participantes para clasificar e interpretar las imágenes fue de buena a excelente (κ de 0,55 a 1). No se encontraron diferencias estadísticamente significativas en el tEG y tTID obtenido por consenso y participantes. El gastroenterólogo fue el más rápido en revisar los procedimientos (51,9 ± 13,5 minutos versus 62,2 ± 19 y 60,9 ± 17,1 para enfermera y residente, respectivamente; p Resumen en inglés Background and aims: capsule endoscopy (CE) allows for a new era in small-bowel examination. Nevertheless, physicians' time for CE-interpretation remains longer than desirable. Alternative strategies to physicians have not been widely investigated. The aim of this study was to evaluate the accuracy of physician extenders in CE-interpretation. Material and methods: one CE-experienced gastroenterologist and two physician extenders reviewed independently 20 CE-procedures. Ea (mas) ch reader was blinded to the findings of their colleagues. A consensus formed by the readers and a second CE-experienced gastroenterologist was used as gold standard. Number, type and location of images selected, character of CE-exams and their relationship with indications were recorded. Gastric emptying time (GEt), small-bowel transit time (SBTt) and time spent by readers were also noted. Results: sensitivity and specificity for "overall" lesions was 79 and 99% for the gastroenterologist; 86 and 43% for the nurse; and 80 and 57% for the resident. All 34 "major" lesions considered by consensus were found by the readers. Agreement between consensus and readers for images classification and procedures interpretation was good to excellent (κ from 0.55 to 1). No significant differences were found in the GEt and SBTt obtained by consensus and readers. The gastroenterologist was faster than physician extenders (mean time spent was 51.9 ± 13.5 minutes versus 62.2 ± 19 and 60.9 ± 17.1 for nurse and resident, respectively; p

Scientific Electronic Library Online (Spanish)

11

Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C/ Recombinant Interferon alfa-2b plus Ribavirin in treatment of chronic hepatitis C

Sánchez Rodríguez, Yoan Antonio; Arús Soler, Enrique; Grá Oramas, Bienvenido; López Saura, Pedro; Nodarse Cuní, Hugo
2010-06-01

Resumen en español El virus de la hepatitis C se ha convertido en la causa principal de hepatitis crónica, cirrosis hepática, hepatocarcinoma, y trasplante de hígado a nivel mundial. OBJETIVO: El presente estudio estuvo dirigido a determinar la evolución virológica, bioquímica e histológica de los pacientes con hepatitis crónica C bajo terapia combinada Interferón a 2b recombinante más ribavirina e identifica los principales factores asociados a las tasas obtenidas de respuesta vi (mas) rológica sostenida. MÉTODOS: Ensayo clínico-terapéutico fase IV, abierto, no controlado y multicéntrico rectorado por el Instituto de Gastroenterología y el Centro de Ingeniería Genética y Biotecnología en el período comprendido de mayo de 2001 a mayo de 2006. La muestra estuvo conformada por 122 pacientes con hepatitis crónica C que cumplieron con criterios de inclusión y exclusión predeterminados. Se utilizó interferón a 2b recombinante (3 millones de unidades 3 veces por semana) más ribavirina (1 000 o 1 200 mg diarios en dependencia del peso corporal) durante 48 sem. RESULTADOS: Se obtuvo una tasa de respuesta virológica y bioquímica sostenida a la semana 72 de 32,8 y 50,8 % respectivamente. Un 41,3 % del total de pacientes experimentó mejoría histológica a expensas de la reducción de la fibrosis y pocos cambios en la inflamación. CONCLUSIONES: Teniendo en cuenta la tasa de respuesta global obtenida, se consideró como tratamiento eficaz para la hepatitis crónica C y se recomendó profundizar en el conocimiento de las características de la infección en Cuba así como en opciones de tratamiento más eficaces para esta enfermedad. Resumen en inglés The hepatitis C virus becomes in leading cause of chronic hepatitis, hepatic cirrhosis, hepatocarcinoma and liver transplant at world level. OBJECTIVE: The aim of present study is to determine the virological, biochemical and histological course of patients presenting with Chronic hepatitis C under a combination of recombinant Interferon alfa-2b plus Ribavirin and to identify the main factors associated with the rates obtained of virological response. METHODS: A non-contr (mas) olled and multicenter phase IV clinical-therapeutical trial was sponsored by the Institute of Gastroenterology and the Genetics and Biotechnology Engineering Center from May, 2002 to May, 2006. Sample included 122 patients diagnosed with chronic hepatitis C fulfilling the predetermined inclusion and exclusion criteria. Recombinant Interferon alfa-2b (3 millions of t.i.d units) was used plus Ribavirin (1000 or 1200 mg daily depending on the body weight) during 48 weeks. RESULTS: We achieved a sustained biochemical and virological response rate of 32.8 and 50.8 %, respectively at week 72. A 41.3,% from the total of patients had a histological improvement at the expense of reduction of fibrosis and a few changes in inflammation level. CONCLUSIONS: Raking into account the global response rate achieved this combined treatment was considered effectiveness for chronic hepatitis C and we recommended to deepen in the knowledge of infection in Cuba, as well as in more efficient treatment options for this disease.

Scientific Electronic Library Online (Spanish)

12

Estudio prospectivo, randomizado, comparativo de la eficacia, seguridad y costos de cefuroxima vs cefradina en la pielonefritis aguda del embarazo/ Efficacy, safety and cost of cefuroxime compared with cephradine in the treatment of acute pyelonephritis during pregnancy

Ovalle S, Alfredo; Martínez T, M Angélica; Wolff R, Marcelo; Cona T, Erna; Valderrama C, Oscar; Villablanca O, Ernesto; Lobos I, Luisa
2000-07-01

Resumen en inglés Background: Second generation cephalosporins (CFPs) are more active in the treatment of acute pyelonephritis during pregnancy but their cost is considerably higher than their predecessors. Cefuroxime, a second generation CFP with oral and parenteral presentations, might offer significant advantages and become a first choice antimicrobial in this setting. Aim: To compare the efficacy, safety and cost of cefuroxime and cephradine in the treatment of acute pyelonephritis in (mas) pregnancy. Patients and methods: Hospitalized women with 12 to 34 weeks of pregnancy, with clinical and bacteriological diagnosis of acute pyelonephritis, were randomly assigned to receive cefuroxime (Curocef (r), GlaxoWellcome) 750 mg t.i.d, i.v or cephradine 1 g q.i.d., i.v. If the isolated organism was resistant to the assigned drug the patient was excluded. Once patients were afebrile, they were switched to an oral form of the same antimicrobial. They were discharged according to the clinical status and treated for a total of 14 days. Laboratory tests, including urine culture were requested during controls and at the end of follow-up at 28 days. Results: One hundred and one patients were randomized: 49 to receive cephradine and 52 to receive cefuroxime. Patients in the cefuroxime group had fewer febrile days (mean 1.7 vs 2.2, p<0.05), faster clinical recovery (mean 2.7 vs 3.1 days, p<0.05), a higher rate of bacteriological cure at 28 days (78.8% and 59.2%, p<0.05) and lower rate of failure (21.2% vs 40.8 % p<0.05). The rate of resistance of isolated uropathogens was l4% to cephradine and 1% to cefuroxime. Conclusions: Cefuroxime can be considered as a first choice option in the treatment of acute pyelonephritis during pregnancy due to its tolerance, microbiological activity and efficacy. (Rev Méd Chile 2000; 128: 749-57)

Scientific Electronic Library Online (Spanish)

13

Estudio Farmacocinético de dos formulaciones de Amoxicilina (500 mg T.I.D. en Cápsulas vs. 750 mg B.I.D. en tabletas dispersibles) en voluntarios humanos sanos

Pérez-González, M; Lamanna, V; Villalobos, J; Bider, A; Sáenz, H; de Nucci, G
2001-02-01

Resumen en español Se evaluó, en voluntarios sanos, el comportamiento de la formulación de 750 mg de Amoxicilina B.I.D., en tabletas dispersibles contra la formulación estándar de 500 mg en cápsulas T.I.D., mediante un estudio de dos vías, entrecruzado con nueve voluntarios sanos. Ambas formulaciones fueron administradas durante un lapso de 6 días consecutivos, con un período de lavado de cuatro semanas antes de cambiar de formulación. Los resultados obtenidos en el día 1 y en el (mas) día 6 del régimen muestran que la concentración máxima alcanzada por la formulación de 750 mg b.i.d., fue significativamente mayor (p Resumen en inglés This study compared Amoxicilin 750 mg b.i.d., (dispersible tablets) and Amoxicilin 500 mg t.i.d., (capsules) in order to determine their bioequivalence. It was a two way, crossover study performed with nine healthy volunteers. Both formulations were administered for 6 consecutive days with a wash period of four weeks. Results at days 1 and 6 showed a rapid absorption of the drug, with a Cmax higher with 750 mg dosage b.i.d., (p(mas) in the time to obtain peak concentration with both formulations. Values of AUC0-24h confirmed that both formulations were bioequivalent. lf we consider a MIC value of 1 µg/mL as a NCSCL, accepted value for otitis and upper respiratory mayor patogen strains with intermediate resistance and calculated how long plasma concentrations are below this value in our study, there was no real difference between formulations, that is strongly supported by the clinical observation that both formulations are equally efficient for the treatment of some important infectious pathologies.

Scientific Electronic Library Online (Spanish)

14

Efecto del clorhidrato de pilocarpina como estimulante de la producción salival en pacientes sometidos a radioterapia de cabeza y cuello/ Effect of pilocarpine hydrochloride on salivary production in previously irradiated head and neck cancer patients

Mosqueda Taylor, Adalberto; Luna Ortiz, Kuauhyama; Irigoyen Camacho, María Esther; Díaz Franco, Marco Antonio; Coll Muñoz, Angel Mario
2004-07-01

Resumen en español Objetivo: Estudiar los efectos del clorhidrato de pilocarpina sobre la producción salival total en pacientes mexicanos con hiposalivación secundaria a radioterapia de la región de cabeza y cuello. Diseño del estudio: Previo consentimiento informado, 20 pacientes con hiposalivación secundaria a radioterapia de la región de cabeza y cuello (> 40 Gy) fueron evaluados mediante el Test de Saliva Global (TSG) antes, durante y al final de 10 semanas de tratamiento con clor (mas) hidrato de pilocarpina (5 mg 3 veces al día). La sintomatología relacionada a la hiposalivación fue evaluada mediante un cuestionario con escala ordinal de 0 a 10. La cantidad de saliva producida al final del tratamiento se comparó con los valores obtenidos al inicio del tratamiento en cada paciente y estos datos fueron analizados mediante la prueba de t de Student pareada. La comparación de los síntomas bucales que incluyeron sensación de humedad, malestar, dificultades para hablar y para deglutir se realizó mediante una prueba de Wilcoxon pareada. Resultados: El TSG basal indicó un promedio de 0.8 cm (d.e. 0.7) de producción salival (rango de 0 a 2.9 cm). Al cabo de las diez semanas de tratamiento el promedio de saliva producido por los pacientes fue de 2.24 cm (d.e..0.7), con un rango de 1.2 a 4.0 cm. El incremento de la producción de saliva fue del 64.5% (p Resumen en inglés Objective: To study the effects of pilocarpine hydrochloride on whole salivary gland production in Mexican patients affected by hyposalivation secondary to radiotherapy of the head and neck region. Study design: With previous written informed consent, 20 patients affected by hyposalivation secondary to head and neck radiation therapy (> 40Gy) were evaluated through the whole saliva test (WST) before, during and after ten weeks of treatment with pilocarpine hydrochloride ( (mas) 5 mg t.i.d.). Hyposalivation-related symptomatology was assessed before and at every week by means of a questionnaire with an ordinal scale ranging from 0-10. Salivary production values recorded at the end of the study and those obtained before treatment were compared by means of Student´s t test. A paired Wilcoxon test was used to compare the differences in the oral symptoms, such as oral dryness, soreness, ability for speaking and swallowing before and after treatment. Results: Initial WST had a mean salivary production of 0.8 cm (s.d. 0.7), with a range from 0 to 2.9 cm). After ten weeks of treatment salivary production increased to a mean of 2.24 cm (s.d. 0.7), with a range from 1.2 to 4.0 cm. There was a salivary flow increase of 64.5% (p

Scientific Electronic Library Online (Spanish)

15

Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? a randomized clinical trial and a meta-analysis of pindolol in nonresistant depression

Portella, Maria J.; Diego-Adeliño, Javier de; Ballesteros, Javier; Puigdemont, Dolors; Oller, Sílvia; Santos, Borja; Álvarez, Enric; Artigas, Francesc; Pérez, Víctor
2010-10-19

Digital.CSIC (Spain)